Published October 22, 2025 | Version v1

May the target be with you: polysaccharide-coated upconverting nanoparticles for macrophage targeting

  • 1. ROR icon National Centre for Nuclear Research
  • 2. Institute of Macromolecular Chemistry of Academy of Sciences of the Czech Republic
  • 3. Lékařská Fakulta Univerzita Palackého v Olomouci
  • 4. ROR icon Palacký University Olomouc
  • 5. ROR icon Adam Mickiewicz University in Poznań
  • 6. ROR icon Czech Academy of Sciences, Institute of Macromolecular Chemistry
  • 7. Institute of Macromolecular Chemistry
  • 8. ROR icon Institute of Physics
  • 9. ROR icon University Hospital Olomouc
  • 10. Palacky University, Faculty of Medicine and Dentistry
  • 11. Institute of Nuclear Chemistry and Technology

Description

Upconversion nanoparticles (UCNPs) based on β-NaYF4 doped with Yb3+ and Er3+ are promising candidates for multimodal bioimaging and theranostic applications, owing to their unique optical properties and favourable safety profile. However, their limited stability under physiological conditions and lack of effective cellular targeting continue to restrict their clinical translation. Here, we report a surface functionalisation strategy using hydroxybisphosphonate-modified polysaccharides-specifically mannan and inulin-to improve both colloidal stability and biological performance of UCNPs. Mannan with grafted hydroxybisphosphonate anchor groups formed a robust coating that prevented aggregation in phosphate-buffered and serum-containing media, while preserving upconversion luminescence. Crucially, the mannan-functionalised surface enabled selective interaction with mannose receptor (MR)-expressing macrophages (J774A.1), facilitating efficient cellular uptake as demonstrated by confocal microscopy and receptor inhibition assays. In vitro studies confirmed the high biocompatibility of mannan-coated UCNPs across a broad concentration range (0.5–10 μg mL−1), with no significant cytotoxicity or oxidative stress observed. This streamlined and effective surface modification approach yields a stable, receptor-targeted nanoplatform with strong potential for future in vivo diagnostic and therapeutic applications involving immune cells.

Files

d5nr01833a.pdf

Files (3.5 MB)

Name Size Download all
md5:fbeb0009186b5d8dba1a03c1a001ff06
3.5 MB Preview Download

Additional details

Funding

National Science Centre
Radiolabelled up-converting nanoparticles as theranostic agents for multimodal imaging and targeted therapy 2024/52/C/ST5/00208